The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of bevacizumab-based treatment in early-onset treatment-naïve metastatic colorectal cancer patients: An ARCAD database analysis.
 
Zhaohui Jin
Consulting or Advisory Role - Novartis (Inst); QED Therapeutics (Inst)
 
Jesse G. Dixon
No Relationships to Disclose
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst); Merck; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Merck (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Cathy Eng
Consulting or Advisory Role - Bayer Health; Gilead/Forty Seven; GlaxoSmithKline; Hookipa Biotech; Mirati Therapeutics; natera; Pfizer
Research Funding - Elevar Therapeutics; Hutchison China Meditech; Merck; Pfizer
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - HalioDx (Inst); Ipsen (Inst); Pfizer (Inst)
Research Funding - Merck (Inst)
 
Jack Fiskum
No Relationships to Disclose
 
Leonard B. Saltz
Research Funding - Taiho Pharmaceutical
 
Herbert I. Hurwitz
No Relationships to Disclose
 
Alan P. Venook
Consulting or Advisory Role - Amgen; BridgeBio Pharma; Exelixis; GlaxoSmithKline; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Hans-Joachim Schmoll
Consulting or Advisory Role - enterome
Research Funding - Bristol-Myers Squibb (Inst)
 
Charles S. Fuchs
Leadership - CytomX Therapeutics; EvolveImmune Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; Entrinsic Health; EvolveImmune Therapeutics
Consulting or Advisory Role - Agios; Amylin; AstraZeneca; AstraZeneca; Bain Capital; CytomX Therapeutics; Daiichi-Sankyo; Entrinsic Health; EvolveImmune Therapeutics; Genentech/Roche; Lilly; Merck; Sanofi; Taiho Pharmaceutical; Unum Therapeutics
Expert Testimony - Amylin; Lilly
 
J. Randolph Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Acrotech Biopharma; Astellas Pharma; Corcept Therapeutics; Gilead Sciences; Merck; Regenacy Pharmaceuticals
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Forty Seven (Inst); Gritstone Bio (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Advaxis; Amgen; Lilly
 
Chiara Cremolini
Honoraria - Amgen; Bayer; Merck; MSD; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; MSD; Roche
Speakers' Bureau - SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER
 
Eduardo Diaz-Rubio
No Relationships to Disclose
 
Cornelis J. A. Punt
Consulting or Advisory Role - Nordic Bioscience (Inst)
 
Niall C. Tebbutt
Honoraria - Bristol-Myers Squibb; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer
 
Volker Heinemann
Honoraria - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Baxalta; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Halozyme; Merck; MSD; MSD Oncology; Roche; Sanofi; SERVIER; Sirtex Medical
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Roche (Inst); Servier (Inst); Shire (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Roche; SERVIER; Shire; Sirtex Medical
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim; Hoosier Cancer Research Network; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)